114 related articles for article (PubMed ID: 21862004)
1. GI perforation associated with bevacizumab.
Yoon SS; Rivera R; Shah A; Ozden N
Gastrointest Endosc; 2012 Jun; 75(6):1286-7. PubMed ID: 21862004
[No Abstract] [Full Text] [Related]
2. Endoscopic management of colonic perforation owing to angiogenesis inhibitors.
Ezzedine S; Bege T; Berdah S; Vitton V; Grimaud JC; Barthet M
Surg Laparosc Endosc Percutan Tech; 2010 Dec; 20(6):e230-2. PubMed ID: 21150409
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab-induced bowel perforation.
Sliesoraitis S; Tawfik B
J Am Osteopath Assoc; 2011 Jul; 111(7):437-41. PubMed ID: 21803880
[TBL] [Abstract][Full Text] [Related]
4. [Surgical management of bevacizumab-associated peritonitis due to perforation].
Kube R; Meyer F; Bien N; Schmidt C; Mroczkowski P; Dalicho S; Lippert H
Zentralbl Chir; 2009 Sep; 134(5):462-7. PubMed ID: 19757347
[TBL] [Abstract][Full Text] [Related]
5. Diaphragmatic rupture, a new complication of Bevacizumab.
Lacaze L; Scotté M
Eur J Surg Oncol; 2012 Nov; 38(11):1079-81. PubMed ID: 22818843
[TBL] [Abstract][Full Text] [Related]
6. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?
Han ES; Monk BJ
Gynecol Oncol; 2007 Apr; 105(1):3-6. PubMed ID: 17383545
[No Abstract] [Full Text] [Related]
7. Gastrointestinal perforation due to bevacizumab in colorectal cancer.
Saif MW; Elfiky A; Salem RR
Ann Surg Oncol; 2007 Jun; 14(6):1860-9. PubMed ID: 17356952
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab-induced perforation of the gastrointestinal tract: clinical and radiographic findings in 11 patients.
Borofsky SE; Levine MS; Rubesin SE; Tanyi JL; Chu CS; Lev-Toaff AS
Abdom Imaging; 2013 Apr; 38(2):265-72. PubMed ID: 22627832
[TBL] [Abstract][Full Text] [Related]
9. [A case of delayed colonic perforation after metallic stent placement for advanced descending colon cancer during bevacizumab-based chemotherapy].
Tanaka I; Hisai H; Miyazaki E; Ono M; Maeda Y; Sato M; Kawasaki R; Gyobu H; Nakajima S; Yamada S; Muramatsu H
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2319-21. PubMed ID: 22202368
[TBL] [Abstract][Full Text] [Related]
10. Gastrointestinal perforation in metastatic carcinoma: a complication of bevacizumab therapy.
Collins D; Ridgway PF; Winter DC; Fennelly D; Evoy D
Eur J Surg Oncol; 2009 Apr; 35(4):444-6. PubMed ID: 18417314
[No Abstract] [Full Text] [Related]
11. Infusion of bevacizumab increases the risk of intestinal perforation: results on a series of 143 patients consecutively treated.
Borzomati D; Nappo G; Valeri S; Vincenzi B; Ripetti V; Coppola R
Updates Surg; 2013 Jun; 65(2):121-4. PubMed ID: 23532741
[TBL] [Abstract][Full Text] [Related]
12. Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study.
Kabbinavar FF; Flynn PJ; Kozloff M; Ashby MA; Sing A; Barr CE; Grothey A
Eur J Cancer; 2012 May; 48(8):1126-32. PubMed ID: 22424880
[TBL] [Abstract][Full Text] [Related]
13. Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management.
Heinzerling JH; Huerta S
Curr Surg; 2006; 63(5):334-7. PubMed ID: 16971205
[TBL] [Abstract][Full Text] [Related]
14. Retrobulbar optic neuritis in a bevacizumab-treated patient with metastatic breast cancer.
Zhou Y; Zhang Y; Yang X; Fan L; Jiang J
Breast J; 2012 Sep; 18(5):502-3. PubMed ID: 22891618
[No Abstract] [Full Text] [Related]
15. Bevacizumab-associated reversible hypotension.
Iqbal K; Chu Q; Mei Q; Chen Y
Clin Oncol (R Coll Radiol); 2007 Dec; 19(10):800-1. PubMed ID: 17825542
[No Abstract] [Full Text] [Related]
16. Reversible posterior leukoencephalopathy syndrome and bevacizumab in breast cancer.
Sclafani F; Giuseppe G; Mezynksi J; Collins C; Crown J
J Clin Oncol; 2012 Sep; 30(26):e257-9. PubMed ID: 22649141
[No Abstract] [Full Text] [Related]
17. [Generation mechanisms and management strategies of adverse reactions to Bevacizumab during cancer treatment].
Ge FJ; Xu JM
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):481-6. PubMed ID: 21029688
[No Abstract] [Full Text] [Related]
18. Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers.
Abu-Hejleh T; Mezhir JJ; Goodheart MJ; Halfdanarson TR
Curr Oncol Rep; 2012 Aug; 14(4):277-84. PubMed ID: 22532266
[TBL] [Abstract][Full Text] [Related]
19. [A case of metachronous gastrointestinal perforation of a patient with metastatic rectal cancer during treatment with bevacizumab-based chemotherapy].
Sadatomo A; Koinuma K; Miki A; Horie H; Yasuda Y
Gan To Kagaku Ryoho; 2013 Jul; 40(7):943-5. PubMed ID: 23863742
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab-induced small bowel perforation in a patient with breast cancer without intraabdominal metastases.
Lecarpentier E; Ouaffi L; Mir O; Berveiller P; Maurel M; Pujade-Lauraine E; Bouillot JL; Veyrie N
Invest New Drugs; 2011 Dec; 29(6):1500-3. PubMed ID: 20676743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
